Company news
Nurix Therapeutics, Inc. (NASDAQ:NRIX) news
Every Nurix Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
August 20, 2026
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
August 4, 2026
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refracto...
August 4, 2026
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class ...
July 21, 2026
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
July 9, 2026
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refract...
June 11, 2026
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexo...
June 8, 2026
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
May 12, 2026
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
April 22, 2026
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
April 8, 2026
Nurix Therapeutics to Participate in Upcoming Investor Conference
April 7, 2026
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Assoc...
March 23, 2026
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
January 28, 2026
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Ca...
January 12, 2026
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th Americ...
December 8, 2025
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients wi...
December 6, 2025
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients wi...
December 6, 2025
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948...
December 1, 2025
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
November 10, 2025
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immun...
November 7, 2025
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
November 3, 2025
Nurix Therapeutics to Participate in Upcoming Investor Conferences
October 30, 2025
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
October 27, 2025
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
October 22, 2025
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
October 22, 2025
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Acros...
October 18, 2025
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
October 9, 2025
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vit...
September 17, 2025
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
July 9, 2025
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Kno...
July 7, 2025
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (N...
June 12, 2025
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (N...
June 12, 2025
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Be...
June 6, 2025
Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
June 2, 2025
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 15, 2025
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th Internation...
May 14, 2025
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Plat...
April 28, 2025
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Deg...
April 25, 2025
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
April 17, 2025
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
April 8, 2025
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
April 2, 2025
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
March 25, 2025
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
March 17, 2025
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
March 13, 2025
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 4, 2025
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
January 28, 2025